Incyte Corporation (INCY) support and resistance · P/E 14, rev $5.14B
Incyte Corporation (INCY) is a biotechnology company listed on US.
This page maps Incyte Corporation (INCY) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new INCY 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the INCY quote page for the session range and the stock page for the full model.
Not investment advice.